Spruce Biosciences Inc (SPRB)

$75.94 -5.56 (-6.82%)
Market Cap 83.28M
Revenue (ttm) 4.91M
Net Income (ttm) -53.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,080.24%
Debt to Equity Ratio 0.10
Volume 31,409
Avg Vol 115,294
Day's Range N/A - N/A
Shares Out 1.07M
Stochastic %K 47%
Beta 3.57
Analysts Strong Sell
Price Target $230.50

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 655 4168
Address:
611 Gateway Boulevard, Suite 740, South San Francisco, United States
neelsen01
neelsen01 Jan. 13 at 2:37 PM
$SPRB Adding under $75 level…
0 · Reply
ignoreo
ignoreo Jan. 13 at 2:27 AM
$SPRB 1) will be approved before they need to dilute/take on additional debt (2028) 2) will be granted PRV, giving them enough cash to reach cashflow breakeven 3) 200m peak sales is highly reasonable 4) co could be close to a $1B company in as few as ~3 years if things go reasonably well if PRV thesis flops (~20% chance), you still probably get a 2x out of this one
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jan. 9 at 12:06 AM
$SPRB 🔋 Recent IPO READY TO 🚀 WLTH 👀 Will do 500% come Mondays earnings Time to load!!
0 · Reply
Moneymike79
Moneymike79 Jan. 8 at 9:40 PM
$SPRB all in
0 · Reply
kingeboue
kingeboue Jan. 8 at 7:28 PM
$SPRB What do people think following today's news? Finances are fine until end of 2027. That was the big risk
2 · Reply
DARKP00L
DARKP00L Jan. 8 at 1:47 PM
$SPRB 08:19 on Jan. 08 2026 Spruce Biosciences Strikes Up To $50M, 42-Month Loan Facility With Avenue Venture Opportunities Fund II #tradeideas
0 · Reply
Diegogogo
Diegogogo Jan. 7 at 10:35 PM
$OMER please pull a $SPRB
2 · Reply
LowFloatOnly
LowFloatOnly Jan. 7 at 8:20 PM
$SUGP $6 , 500k float Hit the treshold (Shorts fails to deliver list) which means dangerously shorted, , same list as $SMX & $SPRB They squeezed 10.000 %
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jan. 7 at 2:46 PM
$IVP pop like $SPRB $GLUE is $SMX 2.0
0 · Reply
BullishGerman
BullishGerman Jan. 6 at 11:48 PM
$SPRB guess is sold too early, congrats to anyone that held through the years
0 · Reply
Latest News on SPRB
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Jan 8, 2026, 8:00 AM EST - 6 days ago

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 2 months ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)

Oct 7, 2025, 10:38 AM EDT - 3 months ago

Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 7, 2025, 9:44 AM EDT - 3 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Oct 6, 2025, 8:00 AM EDT - 3 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Sep 15, 2025, 7:00 AM EDT - 4 months ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

neelsen01
neelsen01 Jan. 13 at 2:37 PM
$SPRB Adding under $75 level…
0 · Reply
ignoreo
ignoreo Jan. 13 at 2:27 AM
$SPRB 1) will be approved before they need to dilute/take on additional debt (2028) 2) will be granted PRV, giving them enough cash to reach cashflow breakeven 3) 200m peak sales is highly reasonable 4) co could be close to a $1B company in as few as ~3 years if things go reasonably well if PRV thesis flops (~20% chance), you still probably get a 2x out of this one
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jan. 9 at 12:06 AM
$SPRB 🔋 Recent IPO READY TO 🚀 WLTH 👀 Will do 500% come Mondays earnings Time to load!!
0 · Reply
Moneymike79
Moneymike79 Jan. 8 at 9:40 PM
$SPRB all in
0 · Reply
kingeboue
kingeboue Jan. 8 at 7:28 PM
$SPRB What do people think following today's news? Finances are fine until end of 2027. That was the big risk
2 · Reply
DARKP00L
DARKP00L Jan. 8 at 1:47 PM
$SPRB 08:19 on Jan. 08 2026 Spruce Biosciences Strikes Up To $50M, 42-Month Loan Facility With Avenue Venture Opportunities Fund II #tradeideas
0 · Reply
Diegogogo
Diegogogo Jan. 7 at 10:35 PM
$OMER please pull a $SPRB
2 · Reply
LowFloatOnly
LowFloatOnly Jan. 7 at 8:20 PM
$SUGP $6 , 500k float Hit the treshold (Shorts fails to deliver list) which means dangerously shorted, , same list as $SMX & $SPRB They squeezed 10.000 %
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jan. 7 at 2:46 PM
$IVP pop like $SPRB $GLUE is $SMX 2.0
0 · Reply
BullishGerman
BullishGerman Jan. 6 at 11:48 PM
$SPRB guess is sold too early, congrats to anyone that held through the years
0 · Reply
Golibajje
Golibajje Jan. 5 at 5:14 PM
$APVO Cash $25.2 million 😳😳 trading at $8M with 1 million float! will run like $SPRB $SMX
2 · Reply
neelsen01
neelsen01 Jan. 2 at 8:32 PM
$SPRB Looking for $500+ in 2027…
1 · Reply
onjonx
onjonx Jan. 2 at 1:45 PM
$SLS will this pull a $SMX and $SPRB move soon
1 · Reply
Catchmeifucan82
Catchmeifucan82 Jan. 2 at 12:58 PM
$SOPA Whoa! Sopa now at 957% Borrow Rate. Been a while since saw a Short Sale Borrow Rate this high. Last time remember BR this high was on $SPRB few months back. 🧐
1 · Reply
JFais
JFais Jan. 1 at 8:00 PM
Entry 2 in this series $SPRB https://seekingalpha.com/instablog/440063-jonathan-faison/6242897-across-the-biotech-universe-sprb?source=tweet
1 · Reply
JFais
JFais Jan. 1 at 4:52 PM
$SPRB (NP) Think ppl underestimating CMC risk (lift needed to scale up), low N launch out of gate (for revenue stacking to be meaningful, will take a LONG time) Have to do inventory build, vendor in South Korea Need to make registrational batches to support 6-month stability
2 · Reply
32axe
32axe Jan. 1 at 8:30 AM
$ASBP Aspire biopharma holding is preparing to turn the $100 billion global drug delivery market upside down with its soluble sublingual technology. $RGC $SPRB $PFE
2 · Reply
Onpoint456
Onpoint456 Jan. 1 at 1:09 AM
$SPRB $CWD $NEGG $OCTO.X $SMX
2 · Reply
Mike22332233
Mike22332233 Dec. 29 at 2:36 PM
$SPRB MASSIVE DILUTION coming between now and the end of JAN … stock could be in the 40’s by that time … that would be the buy point !!!!
1 · Reply
TradeMomentumX
TradeMomentumX Dec. 27 at 6:15 AM
$SPRB Sentiment increasingly tracks operational truth rather than guidance tone. Margins must hold as the company navigates cost pressure. Execution consistency is the fastest path to confidence rebuilding. Investors will likely insist on proof before expanding exposure.
0 · Reply
IN0V8
IN0V8 Dec. 26 at 7:15 PM
$SPRB Watch closely Oppenheimer initiates coverage with outperform rating; PT $283
0 · Reply
Bogwood
Bogwood Dec. 26 at 6:37 PM
$SPRB I purchased some more shares today. BLA still expected in 1Q26, and the risk is a CMC that could further delay commercialization. Why they priced the offering at $68/sh instead of >$100 is beyond me, and the implicit risk for why this opp isn't a free lunch heading into '26
3 · Reply